How to read an FDA drug approval letter

An approval letter reads like a verdict, and after months or years of review it’s tempting to treat it that way — confirm the first line says approved, forward it to the launch team, move on. The letter is doing more specific work than that. A regulatory affairs professional who reads past the first line finds the actual scope of what FDA just certified, what’s still open, and sometimes a start date that hasn’t arrived yet.

What the letter is actually certifying

An NDA approval letter under § 314.105(a) issues once FDA has worked through the refusal grounds in § 314.125 — an incomplete application, inadequate evidence of safety or efficacy, manufacturing methods that don’t ensure identity, strength, quality, and purity, among others — and found that none of them apply. Read that way, the letter is really a record that the application cleared a specific checklist of disqualifying problems, not a general scientific blessing. It’s the positive counterpart to a Complete Response Letter, which is what issues instead when one of those grounds does apply. A BLA approval runs through a parallel but distinct mechanism: under § 601.4, the Center Director’s determination has to cover both the manufacturing establishment and the product itself, which is why a biologics approval reads, correctly, as a finding about the facility as much as the molecule.

Tentative approval and the delayed effective date

A 505(b)(2) application sometimes clears FDA’s scientific review while a patent or exclusivity period tied to the listed drug it relies on — the subject of its own close reading — is still running. In that case the letter grants what FDA calls tentative approval: the agency has finished its review and found the application approvable, but the product is not approved and cannot be marketed until FDA issues a second letter on the later effective date. Reading the word “approved” in a tentative approval letter as the end of the story is a specific, recurring misread — the letter itself generally says so directly, but it’s easy to stop reading once the headline finding looks favorable.

The letter is shorter than most of what regulatory affairs reads, and that brevity is exactly why it rewards a careful read: which finding was actually made, under which section, effective when — and what, if anything, still has to happen before the product can actually reach a patient.